We were delighted to meet with Gregory Branigan (University of Arizona, AZ, USA) to discuss the impact of estrogen therapies on Alzheimer’s disease pathways.
The abstract entitled: ‘Breast Cancer Therapies Reduce Risk of Alzheimer’s Disease and Dementia: Clinic to Bench Translation’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021.
Questions:
- What is the rationale for investigating the impact of estrogen modulating therapy (EMT) exposure on the risk of neurodegenerative disease (NDD) in women with breast cancer? (0:19)
- Could you tell us a little about your short study and its findings? (1:46)
- What is known about the molecular mechanisms underlying this observed risk reduction? (2:36)
- What are the wider implications of these findings? (4:06)
- What future studies are planned? (5:08)
Disclosures: Gregory Branigan has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of AAN Annual Virtual Meeting 2021.
